呲仑帕奈是什么？

On December 3, 2019, Eisai (China) Pharmaceutical Co., Ltd. successfully held the China launch conference of perampanel, marking the official launch of the new third-generation anti-epileptic drug perampanel in China. This means that China’s epilepsy treatment field has officially welcomed the first non-competitive AMPA receptor antagonist, which will bring new treatment methods and means to the majority of epilepsy patients and their families.

Since the new drug marketing application was submitted in September 2018, based on the significant clinical benefits of Parampanel® compared with existing treatment methods, the National Medical Products Administration has granted the drug priority review status. About 12 months later, on September 29, 2019, the State Food and Drug Administration approved the import license for Eisai’s new drug Parampanel. The drug is suitable for the additional treatment of adults and children aged 12 years and above with partial seizures of epilepsy (with or without secondary generalized seizures).

Perampanel is an innovative anti-epileptic drug developed by Eisai Tsukuba Research Institute and is taken orally once daily. The drug is a highly selective, non-competitive AMPA-type receptor antagonist that can reduce the neuronal hyperexcitability associated with epileptic seizures by targeting the glutamate activity of postsynaptic membrane AMPA receptors. Currently, parampanel has received a Level A recommendation from the 2018 AAN/AES Guidelines for combination treatment of refractory partial-onset epilepsy (TRAFE) in adults.

It was approved for marketing in China on September 29, 2019. Unfortunately, due to the short time it was on the market, the drug was not included in the Chinese Medical Insurance List. This means that patients can purchase the drug domestically, but they must purchase it at their own expense. Parampanel sold in China is very expensive, and the huge medical expenses have overwhelmed many patient families. However, according to Medical Companion Brigade, parampanel is more suitable for long-term use by patients and more cost-effective than other versions. Since the exchange rate has been in a state of fluctuation for a long time, the price fluctuates with the exchange rate and is not static. For more information about Parapanel, please contact Medical Companion Travel for details.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: